BTOG Sponsors for 2026

BTOG relies on income from exhibition/sponsorship at education events and annual conference registration fees to allow it to support and educate thoracic oncology health care professionals and to undertake key activities under our three strategic arms – education, research and representation. Sponsorship does not constitute endorsement, recommendation, or favouring by BTOG. BTOG is sponsored by multiple sponsors from the pharmaceutical, medical, and legal industry. Sponsors have solely provided financial sponsorship, and sponsors have not been involved or influenced the content or agenda. These are our sponsors from 1 April 2026 to 31 March 2027.

Diamond Sponsors for 2026

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and Biopharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. With a 100-year heritage in advancing UK science, today AstraZeneca is the UK’s leading biopharmaceutical company. The company is based in five locations across the UK, with its global headquarters in Cambridge. In the UK, around 8,700 employees work in research and development, manufacturing, supply, sales, and marketing. We supply around 36 medicines to the NHS. Please visit www.astrazeneca.co.uk and follow us on Twitter @AstraZenecaUK for more.

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd-uk.com and connect with us @MSDintheUK on LinkedIn, Instagram, X, YouTube and Facebook.

Platinum Sponsors for 2026

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health.

As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need.

Independent since our foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow.

Learn more at https://www.boehringer-ingelheim.com/uk

NP-GB-106937, February 2026

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics.

The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched the Guardant360^® CDx and Guardant360^® Liquid tests for advanced-stage cancer patients, and Guardant Reveal™ for early-stage cancer patients.

Guardant Health aims to partner to address the needs of healthcare systems and individuals eligible for testing. For more information, please visit http://www.guardanthealth.co.uk.

At Johnson & Johnson Innovative Medicine (J&J), we innovate with purpose to lead where medicine is going. We work every day to get in front of cancer, convening the brightest minds to create, nurture and deliver new approaches to detect, intercept and one day eliminate this disease.

With more than three decades of history in oncology our commitment to pioneer new therapeutic advances and continue redefining treatment paradigms in haematologic malignancies and solid tumours is stronger than ever.

Johnson & Johnson: Changing health for humanity

Merck is a science-led organisation dedicated to delivering transformative medicines with the goal of making a meaningful difference in the lives of patients affected by cancer. Our pioneering spirit drives us to help address this need by discovering and delivering innovative approaches to cancer care.

Our oncology research efforts aim to leverage our synergistic portfolio to tackle challenging tumour types in gastrointestinal, genitourinary, and thoracic cancers.

Learn more at https://www.merckgroup.com/uk-en

At Pfizer Oncology, we are dedicated to advancing medicines to make a meaningful difference for people living with cancer. Our focus includes some of the world’s most common cancers, such as breast, genitourinary, haematology-oncology, and lung cancers. Today, we have over 20 approved cancer medicines and biosimilars in the UK.

Over the past 175 years, our ambitions have accelerated, but we continue to celebrate our legacy while pushing forward for our patients. By 2027, we aim to change a billion lives a year. Our motivation today isn’t just to stay the course – it’s to outdo yesterday.

Please visit us online at www.Pfizer.co.uk or follow us on Twitter (@Pfizer_UK), Facebook (@PfizerUK) and Instagram (@pfizeruk).

At Roche UK, we focus our energy and investment in developing tests and treatments that change lives and give us more quality time with the people we love. And, together with others, we’re solving healthcare’s greatest challenges; helping to achieve better results by connecting early diagnosis to targeted treatment and ongoing support.

Healthcare matters to all of us. That’s why we work hard to ensure that all our new medicines are made available to those who need them through the NHS – wherever they live, whatever their circumstances.

In 2020, more than 820 million Roche diagnostic tests were used to confirm, rule out or manage health conditions and over 712,000 patients benefited from our medicines and diabetes monitoring and insulin delivery system. During this period, we contributed £1.26 billion to the UK economy, supporting over 21,000 jobs.

Proud of what we do, we’re here because we care. In the UK we employ over 2,000 brilliant specialists who work together to transform the lives of patients and their loved ones.

That’s what makes us who we are. That’s what makes us Roche UK. For more information, please visit www.roche.co.uk.

At Takeda Oncology, we aspire to cure cancer, with inspiration from patients and innovation from everywhere. We ensure a tight connection from research to development to commercialisation to rapidly meet the needs of the cancer community, optimising our ability to bring transformative medicines to patients. Our demonstrated leadership in the treatment of haematologic cancers and solid tumours combined with cutting-edge science through multiple platforms, partnerships and therapeutic approaches enable us to bring novel medicines to patients worldwide. https://www.takeda.com/en-gb/

Gold+ Sponsors for 2026

Amgen, a global leader in biotechnology since 1980, is dedicated to unlocking the potential of biology for patients suffering from serious illnesses. With a presence in approximately 100 countries, Amgen focuses on six therapeutic areas: oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology, and neuroscience. The company is committed to discovering, developing, manufacturing, and delivering innovative human therapeutics, ensuring the highest ethical standards and quality in all its products and service. www.amgen.co.uk

Gold Sponsors for 2026

BeiGene, which plans to change its name to BeOne Medicines Ltd., is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of nearly 11,000 colleagues spans five continents. To learn more about BeiGene UK please go to beigene.co.uk

Lilly is the world’s largest pharmaceutical company turning science into therapies for nearly 150 years. Today our medicines help more than 51 million people across the globe.

Lilly has a major and long-term commitment to the UK with Lilly UK being our first affiliate business to open outside of the US in 1934. Our UK headquarters is located in Basingstoke and we have an additional research and development site in Bracknell.

Our UK operations have played a central role in our company’s global development. We have around 570 talented employees across the UK, working in roles such as regulatory affairs, medical affairs, sales, marketing and communications.

https://www.lilly.com/uk/

Silver Sponsors for 2026

Axana MDT: The operating system for cancer care. We provide software to support oncology multidisciplinary team meetings. We cover the whole process, starting with the preparation for the MDT, then facilitating the running of it and then moving onto managing the tasks that follow on from it for complete patient management. We unify patient data, present dashboards of analytics, clinical expertise and pharma intelligence through software and AI to give every cancer patient a ﬁghting chance to survive. https://axana.com/

Summit Therapeutics is a biopharmaceutical oncology company focused on addressing serious unmet medical needs. Summit’s compound, ivonescimab, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with anti-angiogenesis effects of anti-VEGF in a single molecule. Ivonescimab displays cooperative binding to these targets with increased avidity in the tumor microenvironment. Summit Therapeutics is currently conducting Phase 3 studies: NSCLC (NCT05899608, NCT06767514), Colorectal Cancer (NCT07228832). Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s NMPA. www.smmttx.com.

Bronze Sponsors for 2026

At Cook Medical, we are passionate about making unique, quality medical devices and connecting with people to improve lives. Founded on inventing, manufacturing, and delivering medical devices, we provide healthcare professionals with the tools they need to help their patients return to living.

Our commitment to innovation involves bringing new products to market and keeping existing products relevant to a changing healthcare landscape. We believe in using our business to help people and communities thrive by creating inclusive, supportive, and healthy environments.

We are proud of our history of innovative firsts and the impact we have on patients and communities. With headquarters in Bloomington, Indiana, and manufacturing facilities and offices in various global locations, we challenge ourselves to maintain a global perspective while focusing on local impact.

Follow Cook Medical at CookMedical.com and on LinkedIn.

At GSK, we unite science, technology and talent to get ahead of disease together.

We prevent and treat disease with specialty medicines, vaccines and general medicines investing in four core therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; infectious diseases.

Our Ahead Together strategy means intervening early to prevent and change the course of disease, helping to protect people and support healthcare systems.

Website: United Kingdom | GSK

Pharmacosmos A/S is a global leader in carbohydrate chemistry and in developing innovative treatments for iron deficiency and iron deficiency anaemia. Building on our foundational expertise in carbohydrate chemistry and cell cycle biology, we are now pioneering new therapies that extend our focus into oncology, including small cell lung cancer. Founded in 1965 and headquartered in Denmark, our team is made up of more than 700 specialists across the UK, Ireland, the Nordics, Germany, the USA, and China.

pharmacosmos.co.uk

Bronze Legal Sponsors for 2025

Hugh James is a leading law firm with offices in Cardiff, London, Manchester, Southampton, and Plymouth. The firm has grown from humble beginnings in 1960 to become a leading law firm, servicing a vast range of clients across the UK and overseas.

Hugh James’ specialist asbestos solicitors represent victims and their families from all over the UK and are highly experienced in investigating asbestos claims to track down the responsible parties. They are experts in their field and have been successfully handling industrial disease and asbestos cases for over 50 years. They provide on-going support to their clients and families they work with, and make sure the legal process is as straightforward as possible.

They are relentless in their pursuit of justice and provide expert legal advice to ensure the best care, treatment and highest level of compensation is received.

hughjames.com

Irwin Mitchell has been at the forefront of securing compensation and improving quality of life for people with mesothelioma and other asbestos‑related diseases for decades. With the largest specialist asbestos legal team in England, Scotland and Wales, our dedicated lawyers are recognised leaders in the field. We have achieved landmark judgments, including pioneering cases funding private medical treatment, and have driven positive changes in the law through numerous successful Appeal Court decisions. Working closely with clients, families and healthcare professionals, we provide holistic, nationwide support. To find out how we can help you or your patients, call 0808 291 3657 or on line

Website: Mesothelioma Compensation Claims | Irwin Mitchell

Leigh Day Lawyers have specialised in asbestos cases for over 30 years, both in the UK and across the globe.

International Legal Directory Chambers and Partners wrote:

Highly respected industrial disease practice offering first-rate representation to claimants suffering asbestos-related diseases. Features prominently in headline disease cases and retains strong links to support groups and non-profits catering for those with mesothelioma.

Our firm’s legal cases have set precedents which other law firms follow. We stand out amongst our contemporaries.

Please visit our stand. We look forward to seeing you.

Our website: Mesothelioma And Me: Spotlighting the dangers of asbestos

Email: asbestos@leighday.co.uk

RWK Goodman are specialist asbestos claims solicitors offering no win no fee no deductions advice and representation to those diagnosed with asbestos related illnesses.

We can be contacted on 0800 051 8056 or by emailing meso@rwkgoodman.com.

Thompsons Solicitors and Thompsons Solicitors Scotland are proud to sponsor BTOG.
Together, we are leading specialists in personal injury and workplace illness claims, with a long-standing commitment to supporting those affected by asbestos‑related disease. Our teams work closely with patients, families, charities, and clinicians to secure justice, raise awareness, and campaign for safer working environments. With dedicated asbestos disease units across England, Wales, Northern Ireland and Scotland, we combine legal expertise with compassionate, client‑focused support.

Websites:

https://www.thompsons.law/services/asbestos-disease-claims

https://www.thompsons-scotland.co.uk/asbestos